Exploring the Role of Novel Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Program Overview

The vast majority of non-Hodgkin‘s lymphoma (NHL) are B-cell NHLs, the most common being diffuse large B-cell lymphoma (DLBCL). While most patients with DLBCL respond to initial therapy, over a third will develop refractory or relapsed (R/R) disease. Although there is no established standard of care, recent approvals of bispecific T-cell engagers, emerging therapies, and developing data are changing the treatment paradigm in R/R DLBCL. In this activity, Drs. Allison Rosenthal and Yasmin Karimi will review the latest conference data on current and emerging bispecific antibodies for R/R DLBCL.

0.5 CE Credit(s)
Expires: August 29, 2024

Target Audience

Oncology and hematology clinicians managing patients with B-cell lymphoma 

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Individualize treatment for patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)
  • Integrate key evidence on emerging immunotherapies, including bispecific antibodies, when personalizing treatment of R/R DLBCL

Activity Faculty

250-23-1135 VL01 YHK Faculty Headshot 1200x1500

Yasmin H. Karimi, MD

Assistant Professor, Medicine
University of Michigan
Ann Arbor, MI

250-23-1135 VL01 Rosenthal Allison C Faculty Headshot 1200x1500

Allison C. Rosenthal, DO

Assistant Professor, Medicine
Medical Director, Adolescent and Young Adult Cancer Program
Mayo Clinic
Phoenix, AZ

Resources

Supporter Statement

This activity is supported by an educational grant from Genmab US, Inc. and AbbVie. 

Provider Statement

Provided by RMEI Medical Education, LLC 

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Yasmin H. Karimi, MD, has relevant financial relationships with ADC Therapeutics SA (Advisor).

Allison C. Rosenthal, DO, has relevant financial relationships with Acerta Pharma, LLC, ADC Therapeutics SA, Celgene, Curis, Inc., GB005 Inc., Genmab US, Inc., Incyte Corporation, LOXO Oncology, Inc., Miltenyi Biotec, Novartis, Zhejiang DTRM Biopharma Co. Ltd. (Grants/Funded Research).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

 

Planners and Managers

RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose with the exception of Claudia Prahst, PhD, medical writer, who had a relevant financial relationship with Foundation Medicine, Inc (Employee). This relevant financial relationship has been divested. 

Joint Accreditation Statement 

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

 

Credit Designation 

Physician Continuing Medical Education 
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Method of Participation and Request for Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at [email protected]. 

Users must: 

  • Read the learning objectives and faculty disclosures 
  • Participate in the activity 
  • Complete the activity evaluation and attest to credit

 

There is no fee to participate.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer Statement

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Copyright Statement

© Copyright 2024. All rights reserved. Developed and managed by RMEI Medical Education, LLC. Laurel Office Plaza | 101 Laurel Road, Suite 200 | Voorhees, NJ 08043 | www.RMEI.com | (866) 770-RMEI

Subscribe

Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources